Advertisement
ALGN vs XRAY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALGN is a Buy and XRAY is a Buy.
ALGN in upward trend: price rose above 50-day moving average on November 02, 2026
ALGN moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 34 of 41 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ALGN as a result. In 58 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 73%.
The Moving Average Convergence Divergence (MACD) for ALGN just turned positive on October 08, 2026. Looking at past instances where ALGN's MACD turned positive, the stock continued to rise in 31 of 42 cases over the following month. The odds of a continued upward trend are 74%.
The 10-day moving average for ALGN crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 11 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
Following a +1.16% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALGN advanced for three days, in 190 of 272 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 43 of 63 cases where ALGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 68%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
ALGN broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. ALGN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.587) is normal, around the industry mean (4.877). P/E Ratio (26.712) is within average values for comparable stocks, (37.682). Projected Growth (PEG Ratio) (0.611) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (2.612) is also within normal values, averaging (56.876).
The Tickeron SMR rating for this company is 69 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
XRAY in upward trend: price rose above 50-day moving average on November 02, 2026
XRAY moved above its 50-day moving average on November 02, 2026 date and that indicates a change from a downward trend to an upward trend. In 28 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where XRAY's RSI Oscillator exited the oversold zone, 30 of 42 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 71%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on XRAY as a result. In 57 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for XRAY just turned positive on October 09, 2026. Looking at past instances where XRAY's MACD turned positive, the stock continued to rise in 29 of 53 cases over the following month. The odds of a continued upward trend are 55%.
Following a +2.78% 3-day Advance, the price is estimated to grow further. Considering data from situations where XRAY advanced for three days, in 172 of 293 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where XRAY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
XRAY broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for XRAY entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.461) is normal, around the industry mean (4.877). P/E Ratio (-3.626) is within average values for comparable stocks, (37.682). Projected Growth (PEG Ratio) (0.601) is also within normal values, averaging (4.143). XRAY's Dividend Yield (0.065) is considerably higher than the industry average of (0.005). P/S Ratio (0.557) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 19 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. XRAY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XRAY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
ALGN | XRAY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 37 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 63 Fair valued | 6 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 69 | 97 | |
PRICE GROWTH RATING 1..100 | 58 | 62 | |
P/E GROWTH RATING 1..100 | 47 | 19 | |
SEASONALITY SCORE 1..100 | 6 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
XRAY's Valuation (6) in the Medical Specialties industry is somewhat better than the same rating for ALGN (63). This means that XRAY’s stock grew somewhat faster than ALGN’s over the last 12 months.
XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as ALGN (100). This means that XRAY’s stock grew similarly to ALGN’s over the last 12 months.
ALGN's SMR Rating (69) in the Medical Specialties industry is in the same range as XRAY (97). This means that ALGN’s stock grew similarly to XRAY’s over the last 12 months.
ALGN's Price Growth Rating (58) in the Medical Specialties industry is in the same range as XRAY (62). This means that ALGN’s stock grew similarly to XRAY’s over the last 12 months.
XRAY's P/E Growth Rating (19) in the Medical Specialties industry is in the same range as ALGN (47). This means that XRAY’s stock grew similarly to ALGN’s over the last 12 months.
| ALGN | XRAY | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 68% | 2 days ago 70% |
| Momentum ODDS (%) | 2 days ago 73% | 2 days ago 63% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 55% |
| TrendWeek ODDS (%) | 2 days ago 73% | 2 days ago 62% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 63% |
| Advances ODDS (%) | 6 days ago 70% | 6 days ago 59% |
| Declines ODDS (%) | 8 days ago 76% | 9 days ago 74% |
| BollingerBands ODDS (%) | 2 days ago 72% | 2 days ago 82% |
| Aroon ODDS (%) | 2 days ago 76% | 2 days ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALGN’s FA Score shows that 0 FA rating(s) are green while XRAY’s FA Score has 2 green FA rating(s).
- ALGN’s FA Score: 0 green, 5 red.
- XRAY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALGN’s TA Score shows that 5 TA indicator(s) are bullish while XRAY’s TA Score has 5 bullish TA indicator(s).
- ALGN’s TA Score: 5 bullish, 4 bearish.
- XRAY’s TA Score: 5 bullish, 4 bearish.
Price Growth
ALGN (@Pharmaceuticals: Other) experienced а +1.23% price change this week, while XRAY (@Pharmaceuticals: Other) price change was +7.38% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -0.77%. For the same industry, the average monthly price growth was -1.95%, and the average quarterly price growth was +10.23%.
Reported Earning Dates
ALGN is expected to report earnings on Feb 03, 2027.
XRAY is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-0.77% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
ALGN and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALGN has been closely correlated with NVST. These tickers have moved in lockstep 71% of the time. This A.I.-generated data suggests there is a high statistical probability that if ALGN jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To ALGN | 1D Price Change % | ||
|---|---|---|---|---|
| ALGN | 100% | +2.83% | ||
| NVST - ALGN | 71% Closely correlated | +5.10% | ||
| XRAY - ALGN | 58% Loosely correlated | +3.88% | ||
| LUNG - ALGN | 52% Loosely correlated | -14.14% | ||
| ICUI - ALGN | 51% Loosely correlated | -0.85% | ||
| ILMN - ALGN | 48% Loosely correlated | -3.99% | ||
More | ||||
XRAY and
Correlation & Price change
A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.
| Ticker / NAME | Correlation To XRAY | 1D Price Change % | ||
|---|---|---|---|---|
| XRAY | 100% | +3.88% | ||
| NVST - XRAY | 62% Loosely correlated | +5.10% | ||
| ALGN - XRAY | 58% Loosely correlated | +2.83% | ||
| QDEL - XRAY | 50% Loosely correlated | +5.89% | ||
| KIDS - XRAY | 48% Loosely correlated | -1.43% | ||
| STE - XRAY | 46% Loosely correlated | +2.74% | ||
More | ||||